Physician profile
Roger C On
NPI 1255334769
$5,061.96
in general payments reported to CMS, 2019-2025
35 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,770 · 2020: $662 · 2021: $995 · 2022: $744 · 2023: $226 · 2024: $427 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.12 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $820.44 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $805.91 | 2019-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $410.00 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $337.88 | 2019-2024 | Wainua |
| Novartis Pharmaceuticals Corporation | $296.68 | 2019-2022 | |
| Pfizer INC. | $284.81 | 2019-2020 | |
| Amgen INC. | $226.31 | 2019-2022 | |
| Akcea Therapeutics, INC. | $215.20 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $180.68 | 2019-2022 | |
| Edwards Lifesciences Corporation | $152.91 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $129.30 | 2019-2022 | |
| Lundbeck LLC | $128.53 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $97.28 | 2019 | |
| Amarin Pharma, INC. | $89.61 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.57 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $87.14 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.71 | 2020-2021 | |
| Novo Nordisk INC | $84.53 | 2021 | |
| Alnylam Pharmaceuticals INC. | $83.71 | 2019 | |
| Abbott Laboratories | $49.66 | 2020 | |
| Bardy Diagnostics, INC. | $45.94 | 2019-2020 | |
| Ibsa Pharma INC. | $40.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.06 | 2019-2020 | |
| Bausch Health US, LLC | $34.71 | 2021-2022 | |
| Insulet Corporation | $34.26 | 2019 | |
| Portola Pharmaceuticals, LLC | $33.19 | 2019 | |
| Mannkind Corporation | $29.60 | 2019 | |
| Lilly USA, LLC | $27.54 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.74 | 2019 | |
| Irhythm Technologies, INC. | $22.03 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2023 | Evkeeza |
| Siemens Medical Solutions USA, INC. | $17.30 | 2024 | Atellica Im 1300 Analyzer |
| Teva Pharmaceuticals USA, INC. | $14.89 | 2021 | |
| Tactile Systems Technology INC | $14.61 | 2020 | |
| Circassia INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger On listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.